

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM769476

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Forma Therapeutics, Inc.		11/15/2022	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Rigel Pharmaceuticals, Inc.		
Street Address:	1180 Veterans Boulevard		
City:	South San Francisco		
State/Country:	CALIFORNIA		
Postal Code:	94080		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Serial Number:	88603967	REZLIDHIA	
Serial Number:	88604010	ONPONDHI	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	4155917506		
Email:	sftrademarks@faegredrinker.com		
Correspondent Name:	Diane J. Mason		
Address Line 1:	Four Embarcadero Center, 27th Floor		
Address Line 4:	San Francisco, CALIFORNIA 94111		
NAME OF SUBMITTER:	Diane J. Mason		
SIGNATURE:	/djm/		
DATE SIGNED:	11/22/2022		
Total Attachments: 1			
source=Rezlidhia assignment signature page#page1.tif			

OP \$65.00 88603967

Trademark Assignment


WHEREAS, Forma Therapeutics, Inc., a Delaware Corporation, having its place of business at 300 North Beacon Street, Suite 501, Watertown, Massachusetts ("Assignor"), is the owner of the following marks (collectively "Trademarks") :

- U.S. Application Serial No. 88603967, filed September 4, 2019, for the mark REZLIDHIA; and
- U.S. Application Serial No. 88604010, filed September 4, 2019, for the mark ONPONDHI;

WHEREAS, Rigel Pharmaceuticals, Inc., a Delaware Corporation, having its place of business at 1180 Veterans Boulevard South San Francisco, California 94080 ("Assignee"), desires to acquire all right, title and interest in and to the Trademarks, together with the associated goodwill;

NOW, THEREFORE, pursuant to the Assignment Agreement entered into between the parties on the 15th day of November, 2022 and for good and adequate consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby assigns to Assignee all rights, title and interest as Assignor may have acquired in and to the Trademarks in the United States, together with (i) the goodwill symbolized by said Trademarks, and (ii) all registrations and applications for the Trademarks.

Executed as of the effective date set forth above.

Forma Therapeutics, Inc.
By: 
Name: <u>Elizabeth Spinney</u>
Title: <u>Executive Director, S&ED Counsel</u>

US 36298777.01